T1	Participants 111 137	granulocytopenic patients.
T2	Participants 413 439	granulocytopenic patients.
T3	Participants 440 683	Patients were stratified into two groups: favorable-prognosis, group 1 (carcinoma, lymphoma, multiple myeloma), or unfavorable-prognosis, group 2 (acute leukemia, bone marrow transplantation), based on anticipated duration of granulocytopenia.
